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We present an unusual case of a late recurrent central neurocytoma that was rediagnosed as an ependymoma and neurocytoma
in accordance with changes in histological classifications. Case Description. A 56-year-old male teacher presented with incomplete
transverse syndrome due to several intradural extramedullary tumors at the level of lumbar vertebrae 1–3.The histological diagnosis
at the time was atypical ependymoma. One year later, two additional tumors were removed at the L5-S1 vertebral level. For 12
years, the patient remained tumor free on followup. Fourteen years after the initial diagnosis, the patient presented with thoracic
paresthesias due to two new extramedullary tumors in the C7-T1 and the T8-T9 vertebral levels. After complete removal of the
tumors, a radiological survey revealed an intracranial lesion in the third ventricle. Fivemonths later, an additional lesion recurrence
was removed surgically.Themost recent histological diagnosis revealed an atypical central neurocytoma. In retrospect, the previous
tumors were reclassified as neurocytoma according to the additional immunohistochemistry evidence. Discussion. There is no
standard adjuvant treatment regimen for atypical neurocytoma; therefore, the patient is currently under close followup. Modern
histopathological diagnosis is essential in these cases. Potential routes for dissemination of the tumor should be considered upon
first recurrence.
1. Introduction
Central neurocytomas are rare benign tumors of the central
nervous system, characterized by their intraventricular local-
ization. They are considered to arise from precursor cells of
the septum pellucidum. They predominantly occur in young
adults and generally have a favorable outcome, although cases
with an aggressive clinical course and recurrences have been
described. Historically, many of these lesions were regarded
as either intraventricular oligodendroglioma or as ependy-
momauntil detailed immunohistological clarification of their
neuronal phenotypes was established. Neurocytoma was first
described by Hassoun et al. [1] and is now a well-established
diagnosis included in the latest WHO Classification [2].
In the literature, only a few neurocytomas were reported
with an extraventricular location, including cerebral hemi-
spheres [3], thalamus [4], cerebellum [5], pons [6], amygdala
[7], retina [8], and in some rare cases the spinal cord [9].
Herein, we report a case of an atypical central neurocy-
toma with recurrent spinal dissemination over a period of 20
years.
2. Case Report
A 56-year-old Caucasian male teacher was first seen by his
general practitioner in September 1991 complaining of back
pain that was treated symptomatically. No imaging studies
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Figure 1: (a) A sagittal postgadolinium T1-weigthed image shows the two lesions before surgery. (b)The tumor at level C7-T1 in T2-weigthed
image. (c) In cranial T1-weighted image, the small tumor is located on the floor of the third ventricle. (d) T1-weighted image shows the
postoperative result.
were arranged at that time. In April 1992, the patient devel-
oped sudden paraplegia of both legs, necessitating emergency
surgery in an outside hospital. After a myelography and post-
myelography-CT, three tumors located in the L1-3 vertebral
level were removed via laminectomy L1-3. The paraplegia
was caused by bleeding within the biggest tumor at the
L1 level. Investigation of the removed tumors showed an
“atypical” ependymoma. Immunohistochemical tests were
not performed at that time. After removal, the neurological
symptoms persisted, including saddle anesthesia, sphincter
disturbance (urinary retention and fecal incontinence), and
weakness of both legs.
In December 1992, a second operation (also in an outside
hospital) was necessary to remove two newly appeared
tumors which were located in the L5-S1 vertebral level. The
histological study of the removed tumors also demonstrated
an atypical ependymoma. Since that time, the patient has
had no new clinical presentations. However, the symptoms
mentioned previously persisted.
In December 2006, the patient was admitted to our
neurosurgical department because of numbness and pain
radiating into the upper part of the body and into both arms.
The spinalMR imaging showed several intramedullary spaces
occupying lesions in the C7-T1 and the T8-T9 vertebral levels
(Figures 1(a) and 1(b)). The large lesion at the level of C7-T1
was completely removed via laminectomy. Intraoperatively,
the tumor appeared intradural extramedullary with direct
contact to the left T1-radix. Complete removal was accom-
plished without causing any postoperative neurological mor-
bidity. In March 2007, removal of the tumor located at the
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T8-T9 vertebral level was undertaken (Figure 1(d)). Again,
the tumor was extramedullary, originating from a spinal
nerve within the cauda equina. Postoperatively, the patient
did not suffer from any complaints and no neurological
worsening was observed.
Due to repeated presentations of multiple ependymoma,
a cranial MRI was obtained for the first time. This revealed a
contrast enhancing intracerebral mass in the third ventricle
(Figure 1(c)). The cranial mass did not cause any symptoms.
In particular, no visual field deficits or hormonal disturbances
were detectable.The patient refused any surgical intervention
to treat the cranial tumor and preferred close follow-up
investigations.
In the MR imaging studies of the cranium and spinal axis
in September 2010 and 2012, no new tumors were seen and
progression of the cranial tumor was indiscernible.
3. Histology
Histology demonstrated a mostly monomorphic, highly cel-
lular tumor with rounded chromatin intense nuclei, mostly
without nucleoli or mitoses (Figures 2(a) and 2(b)). Nuclear
pleomorphy was low and was lacking atypical mitoses. A
regular rete-like network of otherwise inconspicuous cap-
illaries was distributed throughout the tumor. Rosettes of
fully differentiated ganglion cells were absent. Likewise, the
intratumoral matrix showed only mild fibrillary content
with marked absence of typical glial fiber networks. The
walls of larger blood vessels appeared slightly hyaline with
thickened ends. Inflammation was mostly absent. Immuno-
histochemistry revealed a strong positive reaction for the
neuronal marker synaptophysin and for the antibody to
𝛽III Tubulin (Figures 2(c) and 2(d)) demonstrating mostly
immature neurons in 100% of the tumor cells. Chromo-
granin, a marker for mature, differentiated neurons and
ganglion cells, was mostly negative (Figure 2(e)). GFAP (not
shown) and S100 were mostly negative with the excep-
tion of single cells of glial morphology (Figure 2(f)). Only
few proliferating cells (up to 5% maximum) could be
ascertained with the marker Ki67/MIB-1 (Figure 2(b)). The
tumor was evaluated as atypical neurocytoma (equivalent
to WHO grades II-III) due to increased cellularity and
slightly elevated counts of proliferating cells. An ependy-
moma could be mostly excluded on the basis of lacking
GFAP stain. In comparison, the tumor tissues excised in
2006 showed a similar tumor pattern, with slightly lower
cellularity and perivascular nucleus-free neuropil, typical of
neurocytoma (Figure 2(g)). Immunohistochemical evalua-
tion also showed the same expression pattern as the tumor
from the surgery in 2007, with a positive immunoreac-
tion for synaptophysin and a negative reaction for GFAP.
Slides of the tumor excised in 1992 also showed a similar
morphology (Figure 2(h)) and a similar reaction pattern,
with a slightly lower proliferation rate as compared to 2007,
and a negative immunoreaction for GFAP (not shown). In
retrospect, both tumor tissues were reclassified as neuro-
cytoma, which did not show atypical morphology in both
instances.
4. Discussion
Central neurocytomas are benign tumors of the central
nervous system which predominantly occur in young adults
and generally have a favorable outcome. Neurocytomas are
typically located in the lateral ventricles in the region of
foramen Monro (central neurocytoma) or within the brain
parenchyma (extraventricular neurocytoma).
Atypical neurocytomas, which are neurocytomas with
a MIB-1 LI >2% with/without anaplastic features [15, 16],
have been noted to have worse clinical outcome and higher
recurrence rate comparedwith normal neurocytomas [16, 17].
So¨ylemezoglu et al. observed that patients with neurocytoma
MIB-1 LI <2% had a relapse rate of 22% after a followup
of 150 months compared with 63% when it was >2%. Thus,
they concluded that a MIB-1 LI >2% might be critical in
determining recurrence. Rades et al. have suggested that a
MIB-1 LI score >3% is associated with an adverse outcome
[18]. In our case, the last removed tumor in March 2007
exhibited a MIB-1 LI of 5%.
Despite the usually benign nature of this tumor, eight
cases with ventricular or spinal dissemination have been
reported in the literature (Table 1). Sharma et al. reported a
rare case of a spinal neurocytoma with a retrograde caudo-
cranial CSF dissemination in a 24-year-old patient [9]. The
dissemination pattern of the presented case was difficult to
investigate since cranial imaging studies were not performed
upon initial presentation. In our case, it remains difficult to
determine whether the patient actually suffered a retrograde
dissemination of the tumor or whether the tumor originally
consisted of a small central neurocytoma with long-term
spinal dissemination through the ventricular system. One
potential argument in favor of the latter notion is the fact that,
in 2006, the previous tumor showed the typical morphology
of a central neurocytoma without atypia and may have
grown very slowly over time. Atypical behavior clearly only
developed recently. Although not obviously malignant, the
biological behavior of this tumor has to be regarded as
uncertain.
Pitfalls of the pathological diagnosis consist of mor-
phology very similar to ependymoma, which also contains
perivascular acellular areas, but subtly fewer monomorphic
nuclear shapes and a more fibrillar matrix. In this case, the
first diagnosis of an ependymoma which is much more likely
in this location was based only upon morphology. However,
using immunohistochemistry, it was possible to reach the
correct diagnosis of neurocytoma. Paraganglioma repre-
sents a further differential diagnosis of spinal neurocytoma.
Immunohistochemical differentiation between these two
entities is considerably more difficult since both tumors show
expression of neuronal markers; however, paraganglioma
should also show expression of chromogranin and at least
somemore mature neural cells. Furthermore, paraganglioma
usually contains a morphological “Zellballen” pattern and
sustentacular cells at regular intervals with positive staining
of S100 [19]. These specific features are absent in the tumor
described in this report. Also, the clinical course of our
patient with intraspinal localization of the tumors and the
intracerebral lesion makes a paraganglioma very unlikely in





Figure 2: Tumor histomorphology at different time points. (a) In 2007, excised mostly monomorphic highly cellular tumor with regular
rounded nuclei and only fewmitoses.The blood vessels are regularly arranged resembling a loose meshwork without pathological endothelial
proliferation or glycogen storage. (Periodic acid Schiff (PAS), Magnification original ×20.) (b) Immunostaining for the proliferation marker
K67 (MIB-1) showing only few proliferating cells (indirect peroxidise technique (LSABII, DAKO, diaminobenzidine (DAB) as a chromogen,
brown, Magnification original ×20, counterstaining with Hematoxylin)). (c) Immunostaining for 𝛽-III-Tubulin (Chemicon), a marker of
immature neural cells with strong positivity of all tumor cells. (LSABII, DAKO, (DAB), counterstaining with Hematoxylin Magnification
original ×20.) (d) Immunostaining for the neuronal marker synaptophysin (Dako) with strong positive staining of all tumor cells. (LSABII,
DAKO, (DAB), counterstaining with Hematoxylin Magnification original ×20.) (e) Immunostaining for chromogranin (Dako), a marker
of highly differentiated neuronal cells and ganglion cells with mostly negative staining results. (LSABII, DAKO, (DAB), counterstains with
Hematoxylin Magnification original ×20.) (f) Immunostaining for S100 (Dako) showing a mostly negative staining result with single positive
cells of glial morphology at irregular intervals (LSABII, DAKO, (DAB), counterstaining with Hematoxylin Magnification original ×20.) (g)
Tumor biopsy of 2006 with similar morphology of lower cellularity. Noteworthy are the occasional cell-free areas. (H&E, Magnification
original×10.) (h) Tumor biopsy of 1992 showing similarly organized tumor cells with rounded nuclei and even lessmitoses within an extensive
hemorrhage. (H&E, Magnification original ×20.)
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Table 1: Reported cases of neurocytoma with dissemination.
Case number Authors and year Location of the primary tumor MIB-1 LI (%) Location of the dissemination
1 Sharma et al., 2005 [9] C5-T1 spinal segments 9% Intraparenchymal cerebellar
2 Takao et al., 2003 [10] Lateral ventricle 4.6% Local and spinal dissemination
3 Brandes et al., 2000 [11] Septum pellucidum Unknown Ventricular and spinaldissemination
4 Elek et al., 1999 [12] Lateral ventricle 4.4% Local, ventricular, andleptomeningeal dissemination
5 Eng et al., 1997 [13] Septum pellucidum 3.3% Local, ventricular, and spinaldissemination
6 Eng et al., 1997 [13] Lateral ventricle 1.8% Local and leptomeningealdissemination
7 Tomura et al., 1997 [14] Lateral ventricle Unknown Ventricular dissemintaion
8 Tomura et al., 1997 [14] Lateral ventricle Unknown Local and ventricular dissemination
MIB-1 LI: MIB-1 Labeling index.
this case. A further argument towards the neurocytoma is the
slightly different morphology of the previous tissue obtained
in 2006 which shows even more clearly defined aspects of
a neurocytoma. The age of the patient (42 years at first
appearance of symptoms) is slightly above the median age in
neurocytoma patients, which occurs mainly in young adults.
The recurrence and dissemination pattern over 10 years is also
highly unusual.
In summary, the case is of interest to the readership due
to its unusual course, intracerebral spread, and long duration
with only incidental pathology, as well as its ambiguous his-
tological interpretation over the years and neuropathological
classification. Early cranial imaging studies are considered
upon repeated spinal recurrences to exclude a primary
“seeding” tumor.
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